Innovotech Tests Novel Products on Fire Blight

EDMONTON, ALBERTA--(Marketwire - Oct. 7, 2008) - Innovotech Inc. (TSX VENTURE: IOT.V) has signed an agreement with Agriculture and Agri-Food Canada (AAFC) to test several proprietary product candidates on the bacteria responsible for Fire Blight which has caused extensive worldwide damage to fruit trees this year. Initial laboratory testing conducted by Innovotech has shown that the products kill the bacteria responsible for Fire Blight at very low concentrations making this a viable alternative to existing control measures. Innovotech will be working with AAFC scientists to determine if these products are safe and effective on infected plants. The tests are being conducted at two AAFC research sites in Canada; the Pacific Agri-Food Research Centre in Summerland, British Columbia and at the Atlantic Food and Horticulture Research Centre in Kentville, Nova Scotia.

The Pacific Agri-Food Research Centre has published research papers indicating that approximately 50% of bacteria causing Fire Blight in the Okanagan Valley are resistant to the antibiotic Streptomycin, the current treatment of choice. With few products available to producers, Canada and other countries are seeking effective and safe alternatives for Fire Blight.

Response to this outbreak has varied by country with Switzerland resorting to removing infected apple trees and Austria considering an emergency re-introduction of previously banned Streptomycin.

Fire Blight affects apple, pear, strawberry and other fruit bearing and ornamental plants and shows symptoms of weeping canker wounds and blackened leaves.

About Innovotech Inc:

Innovotech is a product development company focusing on the development of solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are protected communities of microorganisms which are very common and very difficult to treat due to their inherent resistance. They have been implicated in a host of devastating infections in agriculture, human health and industry. No diagnostics or antibiotics are currently approved for use in infections involving biofilms.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts

Wolfgang Muhs
Innovotech Inc.
CEO
(780) 448-0585 ext 226
(780) 424-0941 (FAX)
Email: wolfgang.muhs@innovotech.ca

Ken Boutilier
Innovotech Inc.
President
(780) 448-0585 ext 221
(780) 424-0941 (FAX)
Email: ken.boutilier@innovotech.ca